Cancer BiologyNature CommunicationsPeer-reviewed
KMT2A oncoproteins induce epigenetic resistance to targeted therapies
Derek H. Janssens, Melodie Duran, Dominik J. Otto…·Steven Henikoff
This study shows KMT2A oncoproteins drive lineage-switching and epigenetic resistance in leukemia by dynamically binding chromatin and persisting as ENL-marked lesions despite therapy.